Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 575 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Vaccine 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

NCT00953524
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
15
States / cities
Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

NCT00836953
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Pediatric formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 36 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

High-risk Influenza Vaccine Alert

NCT05492786
View directory record Official record
Conditions
Influenza
Interventions
Alert, Salient alert features, High-risk Text, Risk factors
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
80,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

NCT01934127
View directory record Official record
Conditions
Influenza
Interventions
Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 64 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
6
States / cities
Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 12, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease

NCT02883426
View directory record Official record
Conditions
Influenza
Interventions
H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV), H3N2v inactivated subvirion influenza vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 12, 2026, 5:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving the Collaborative Health of Adult Dyads

NCT05370014
View directory record Official record
Conditions
Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Chronic Disease, Stroke, Heart Failure Chronic, Hypertension (HTN)
Interventions
Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Flublok or Fluzone With Advax-CpG55.2 or AF03

NCT03945825
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
AF03, Delta Inulin-CpG55.2, Influenza Virus Quadrivalent Inactivated Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

NCT06508320
View directory record Official record
Conditions
Influenza, SARS-CoV-2
Interventions
mRNA-1083
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
931 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
12
States / cities
Hialeah, Florida • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

NCT00231907
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 35 Months
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 12, 2026, 5:24 PM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

NCT05945485
View directory record Official record
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

NCT02035696
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 48 Months
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

NCT00764790
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 12, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conectados: Social Networks and Social Media for Vaccine Uptake

NCT07096245
View directory record Official record
Conditions
Vaccination
Interventions
Vaccine Information Video Dissemination
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 12, 2026, 5:24 PM EDT